Literature DB >> 12605027

Acute reduction of myocardial infarct size by a hydroxymethyl glutaryl coenzyme A reductase inhibitor is mediated by endothelial nitric oxide synthase.

Sebastian Wolfrum1, Michael Grimm, Marc Heidbreder, Andreas Dendorfer, Hugo A Katus, James K Liao, Gert Richardt.   

Abstract

In addition to their lipid-lowering properties, statins improve endothelial function by increasing the activity of endothelial nitric oxide synthase (eNOS). It was hypothesized that, by this mechanism, statins protect the myocardium from ischemia/reperfusion injury in normocholesterolemic animals. Rats were pretreated for 1 week with either cerivastatin (0.3 mg/kg/d) or placebo. Anesthetized animals underwent 30 minutes of coronary artery occlusion (CAO) followed by 180 minutes of reperfusion. In a separate set of experiments, the NOS inhibitor l-NAME (15 mg/kg; N -nitro-l-arginine methyl ester) was administered 15 minutes before CAO. Cerivastatin decreased infarct size by 49% (P < 0.05) without reducing plasma cholesterol levels. Cerivastatin increased myocardial eNOS mRNA and NOS activity and by 52% and 58% (P < 0.05), respectively. Cardioprotection and upregulation of eNOS activity evoked by cerivastatin were not observed in rats cotreated with l-NAME. These results show that statins reduce the extent of myocardial necrosis in normocholesterolemic rats after acute ischemia/reperfusion injury by increasing myocardial eNOS activity. Therefore, statins may protect the heart not only by reducing the incidence of ischemic events, but also by limiting cell damage during acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605027     DOI: 10.1097/00005344-200303000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  16 in total

1.  Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice.

Authors:  Richard A Miller; David E Harrison; C M Astle; Joseph A Baur; Angela Rodriguez Boyd; Rafael de Cabo; Elizabeth Fernandez; Kevin Flurkey; Martin A Javors; James F Nelson; Carlos J Orihuela; Scott Pletcher; Zelton Dave Sharp; David Sinclair; Joseph W Starnes; J Erby Wilkinson; Nancy L Nadon; Randy Strong
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-10-25       Impact factor: 6.053

Review 2.  Rho kinase (ROCK) inhibitors.

Authors:  James K Liao; Minoru Seto; Kensuke Noma
Journal:  J Cardiovasc Pharmacol       Date:  2007-07       Impact factor: 3.105

3.  Establishing the correlation between statins and cough: case series report and analysis of adverse drug reactions in the international databases.

Authors:  Carla Carnovale; Paolo Pellegrino; Valentina Perrone; Marta Gentili; Tatiana Brusadelli; Stefania Antoniazzi; Alessia Speziali; Cecilia Borsadoli; Marco Pozzi; Emilio Clementi; Sonia Radice
Journal:  Eur J Clin Pharmacol       Date:  2014-09-24       Impact factor: 2.953

4.  Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial.

Authors:  Ahmed A Khattab; Gjin Ndrepepa; Stefanie Schulz; Franz-Josef Neumann; Julinda Mehilli; Heinz Joachim Büttner; Jürgen Pache; Melchior Seyfarth; Josef Dirschinger; Adnan Kastrati; Peter B Berger; Albert Schömig; Gert Richardt
Journal:  Clin Res Cardiol       Date:  2011-02-11       Impact factor: 5.460

Review 5.  Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

Authors:  Kirtiman Srivastava; Philip M W Bath; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2011-12-25       Impact factor: 5.046

6.  Neuroprotection Mediated by Upregulation of Endothelial Nitric Oxide Synthase in Rho-Associated, Coiled-Coil-Containing Kinase 2 Deficient Mice.

Authors:  Yukio Hiroi; Kensuke Noma; Hyung-Hwan Kim; Nikola Sladojevic; Corey E Tabit; Yuxin Li; Guray Soydan; Salvatore Salomone; Michael A Moskowitz; James K Liao
Journal:  Circ J       Date:  2018-01-19       Impact factor: 2.993

7.  Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure.

Authors:  A D Gavin; A D Struthers
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

Review 8.  The cardioprotective effects of statins.

Authors:  Jean Davignon
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

9.  Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection.

Authors:  Sebastian Wolfrum; Andreas Dendorfer; Yoshiyuki Rikitake; Timothy J Stalker; Yulan Gong; Rosario Scalia; Peter Dominiak; James K Liao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-08-19       Impact factor: 8.311

10.  Prehemorrhage statin use and the risk of vasospasm after aneurysmal subarachnoid hemorrhage.

Authors:  Shaye I Moskowitz; Christine Ahrens; J Javier Provencio; Michael Chow; Peter A Rasmussen
Journal:  Surg Neurol       Date:  2008-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.